Literature DB >> 28011330

Current progress in immunotherapy of hepatocellular carcinoma.

Martin F Sprinzl1, Peter R Galle2.   

Abstract

Entities:  

Keywords:  Checkpoint inhibitors; Immunotherapy; Liver cancer; Therapy

Mesh：

Year:  2016        PMID： 28011330     DOI： 10.1016/j.jhep.2016.12.009

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  20 in total

Review 1.  Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.

Authors:  Zuyuan Lin; Di Lu; Xuyong Wei; Jianguo Wang; Xiao Xu
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

Review 2.  Targets for immunotherapy of liver cancer.

Authors:  Tim F Greten; Bruno Sangro
Journal:  J Hepatol       Date:  2017-09-18       Impact factor: 25.083

Review 3.  Immune checkpoint therapy in liver cancer.

Authors:  Feng Xu; Tianqiang Jin; Yuwen Zhu; Chaoliu Dai
Journal:  J Exp Clin Cancer Res       Date:  2018-05-29

4.  miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model.

Authors:  Elisa Callegari; Lucilla D'Abundo; Paola Guerriero; Carolina Simioni; Bahaeldin K Elamin; Marta Russo; Alice Cani; Cristian Bassi; Barbara Zagatti; Luciano Giacomelli; Stella Blandamura; Farzaneh Moshiri; Simona Ultimo; Antonio Frassoldati; Giuseppe Altavilla; Laura Gramantieri; Luca Maria Neri; Silvia Sabbioni; Massimo Negrini
Journal:  Mol Ther Nucleic Acids       Date:  2018-04-12       Impact factor: 8.886

5.  Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer.

Authors:  Dai Liu; Xiaoqiang Qi; Yariswamy Manjunath; Eric T Kimchi; Lixin Ma; Jussuf T Kaifi; Kevin F Staveley-O'Carroll; Guangfu Li
Journal:  J Immunol Res Ther       Date:  2018-06-08

6.  A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment.

Authors:  Yu-Tzu Liu; Tai-Chung Tseng; Ruey-Shyang Soong; Chun-Yi Peng; Yu-Hsing Cheng; Shiu-Feng Huang; Tsung-Hsien Chuang; Jia-Horng Kao; Li-Rung Huang
Journal:  J Immunother Cancer       Date:  2018-12-07       Impact factor: 13.751

7.  Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.

Authors:  Eric Assenat; Georges-Philippe Pageaux; Simon Thézenas; Jean-Marie Peron; Yves Bécouarn; Jean-François Seitz; Philippe Merle; Jean-Frédéric Blanc; Olivier Bouché; Mohamed Ramdani; Sylvain Poujol; Hélène de Forges; Marc Ychou; Valérie Boige
Journal:  Br J Cancer       Date:  2019-04-04       Impact factor: 7.640

Review 8.  Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine.

Authors:  Jingxian Duan; Yuling Wu; Jikui Liu; Jiajia Zhang; Zhichao Fu; Tieshan Feng; Ming Liu; Jie Han; Zhicheng Li; Shifu Chen
Journal:  J Hepatocell Carcinoma       Date:  2019-10-18

9.  Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.

Authors:  Yue Zhao; Timothy Wai Ho Shuen; Tan Boon Toh; Xue Ying Chan; Min Liu; Sue Yee Tan; Yong Fan; Hechuan Yang; Shridhar Ganpathi Lyer; Glenn Kunnath Bonney; Eva Loh; Kenneth Tou En Chang; Thiam Chye Tan; Weiwei Zhai; Jerry Kok Yen Chan; Edward Kai-Hua Chow; Cheng Ean Chee; Guan Huei Lee; Yock Young Dan; Pierce Kah-Hoe Chow; Han Chong Toh; Seng Gee Lim; Qingfeng Chen
Journal:  Gut       Date:  2018-03-30       Impact factor: 23.059

10.  Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy.

Authors:  Hai-Long Chen; Han-Yue OuYang; Yong Le; Peng Jiang; Hui Tang; Zi-Shan Yu; Min-Ke He; Yun-Qiang Tang; Ming Shi
Journal:  Cancer Med       Date:  2018-10-10       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.